Forte Biosciences Inc. (FBRX)
NASDAQ: FBRX
· Real-Time Price · USD
11.85
1.03 (9.52%)
At close: Aug 15, 2025, 3:59 PM
11.61
-2.03%
After-hours: Aug 15, 2025, 04:53 PM EDT
Forte Biosciences Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 10K | 9K | 6K | 3K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 9K | 13K | 14K |
Gross Profit | n/a | n/a | n/a | -10K | -9K | n/a | -3K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -9K | -13K | -14K |
Operating Income | -16.12M | -7.35M | -8.63M | -12.82M | -7.8M | -6.38M | -10.22M | -9.03M | -6.86M | -4.94M | -3.42M | -3.02M | -2.51M | -3.3M | -7.7M | -5.75M | -4.74M |
Interest Income | n/a | n/a | n/a | n/a | n/a | 1.12M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -15.66M | -7.16M | -8.39M | -12.51M | -7.42M | -5.87M | -9.96M | -8.9M | -6.75M | -4.88M | -3.4M | -3.04M | -2.57M | -3.34M | -7.75M | -5.81M | -4.8M |
Net Income | -15.66M | -7.16M | -8.39M | -12.51M | -7.42M | -5.87M | -9.96M | -8.9M | -6.65M | -4.88M | -3.38M | -3.05M | -2.62M | -3.34M | -7.75M | -5.81M | -4.8M |
Selling & General & Admin | 3.43M | 2.12M | 2.76M | 7.08M | 3.44M | 2.81M | 3.85M | 1.9M | 2.07M | 2.45M | 2.04M | 1.99M | 1.82M | 1.95M | 2.04M | 2.22M | 1.42M |
Research & Development | 12.54M | 5.23M | 5.72M | 5.74M | 4.35M | 3.57M | 6.37M | 7.14M | 4.79M | 2.49M | 1.38M | 1.03M | 693K | 1.35M | 5.66M | 3.52M | 3.32M |
Other Expenses | 150K | n/a | 150K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 23K | -15K | n/a | n/a | -52K | n/a | n/a |
Operating Expenses | 16.12M | 7.34M | 8.63M | 12.82M | 7.79M | 6.38M | 10.22M | 9.03M | 6.86M | 4.94M | 3.42M | 3.02M | 2.51M | 3.3M | 7.7M | 5.75M | 4.74M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 102K | n/a | n/a | n/a | 6K | n/a | 15K | 53K | 42K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -9K | -6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 7.35M | 8.63M | 12.82M | 7.8M | 6.38M | 10.22M | 9.03M | 6.86M | 4.94M | 3.42M | 3.02M | 2.51M | 3.3M | 7.7M | 5.75M | 4.74M |
Income Tax Expense | n/a | 34.28K | n/a | n/a | -34.28K | n/a | -3K | -9.03K | -102K | 6K | -23K | 15K | 53K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 11.4M | 6.39M | 1.85M | 1.85M | 1.55M | 1.45M | 1.51M | 841.87K | 840.27K | 840K | 757.1K | 590.45K | 590.39K | 590.18K | 569.65K | 544.13K | 530.12K |
Shares Outstanding (Diluted) | 11.4M | 6.39M | 1.85M | 1.85M | 1.55M | 1.45M | 1.51M | 841.87K | 840.27K | 840K | 757.1K | 590.45K | 590.39K | 590.18K | 569.65K | 544.13K | 530.12K |
EPS (Basic) | -1.37 | -3 | -4.54 | -6.78 | -4.77 | -4.04 | -6.57 | -10.57 | -8.04 | -5.81 | -4.49 | -5.14 | -4.35 | -5.66 | -13.61 | -10.68 | -9.06 |
EPS (Diluted) | -1.37 | -3 | -4.54 | -6.78 | -4.77 | -4.04 | -6.57 | -10.57 | -8.04 | -5.81 | -4.49 | -5.14 | -4.35 | -5.66 | -13.61 | -10.68 | -9.06 |
EBITDA | -16.12M | -7.34M | -8.62M | -12.81M | -7.79M | -6.38M | -10.21M | -9.03M | -6.86M | -4.94M | -3.42M | -3.02M | -2.51M | -3.3M | -7.69M | -5.73M | -4.73M |
EBIT | n/a | -7.35M | -8.63M | -12.82M | -7.8M | -6.38M | -10.22M | -9.03M | -6.86M | -4.94M | -3.42M | -3.02M | -2.51M | -3.3M | -7.7M | -5.75M | -4.74M |
Depreciation & Amortization | n/a | 10K | 10K | 10K | 9K | 6K | 3K | 9.03M | 6.86M | 9K | 9K | 9K | 9K | -42K | 9K | 13K | 14K |